Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (ANAB)
NASDAQ:ANAB
ANAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.21 - $41.31
Previous CloseN/A
Volume154.73K
Average Volume (3M)536.51K
Market Cap
$691.03M
Enterprise ValueN/A
Total Cash (Recent Filing)$385.37M
Total Debt (Recent Filing)$16.04M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 11, 2025EPS Estimate
-1.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding29,380,495
10 Day Avg. Volume673,698
30 Day Avg. Volume536,512
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)7.59
Price to Sales (P/S)0.00
P/FCF Ratio-4.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$50.86Price Target Upside139.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
AnaptysBio News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsRosnilimab's Phase 2b trial results showed strong efficacy and durability with a competitive profile, demonstrating a quick onset of action in rheumatoid arthritis patients.
Investor SentimentShares have risen 76% as investors view ANAB's Jemperli royalty value as a baseline and rosnilimab's differentiated efficacy and safety profile continues to drive positive sentiment.
Safety ProfileRosnilimab showed a clean safety profile with low discontinuation rates and no drug-related serious adverse events, making it favorable compared to existing rheumatoid arthritis treatments.
Bears Say
Comparative Clinical TrialsPeresolimab was discontinued in Phase 2b by Lilly due to misalignment of results with Phase 2a, contrasting with the ongoing trials for rosnilimab.
Financial PerformanceANAB reported a net loss of $38M, which was higher than the estimated $22M.
Stock BuybackThe company announced a $75M stock repurchase program, which may impact the liquidity available for other investments or initiatives.
Ownership Overview
43.85% Insiders
21.76% Mutual Funds
0.91% Other Institutional Investors
22.15% Public Companies and Individual Investors
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $12.21 and its highest was $41.31 in the past 12 months.
What is AnaptysBio Inc’s market cap?
AnaptysBio Inc’s market cap is $691.03M.
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is Aug 11, 2025 which is in 66 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on May 05, 2025. The company reported -$1.28 earnings per share for the quarter, missing the consensus estimate of -$1.253 by -$0.027.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -1.52.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 29,380,495 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of -$1.28 in its last earnings report, missing expectations of -$1.253. Following the earnings report the stock price went down -2.943%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Currently, no hedge funds are holding shares in ANAB
AnaptysBio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.86 (139.12% Upside)
$50.86 (139.12% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.36%
12-Months-Change
Fundamentals
Return on Equity
-343.83%
Trailing 12-Months
Asset Growth
4.00%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
ANAB Stock 12 Month Forecast
Average Price Target
$50.86
▲(139.12%Upside)